Compound profile

KPV

The alpha-MSH fragment studied for calming inflammation

What KPV is, how it keeps alpha-MSH's anti-inflammatory action without the side effects, why it can work orally in the gut, what the preclinical evidence shows, and its 2026 legal status.

How it works

The mechanism

The anti-inflammatory part of a bigger hormone, trimmed down to three amino acids.

An alpha-MSH fragment

It is the last three residues of alpha-MSH, keeping its anti-inflammatory activity but not meaningfully binding the melanocortin receptors behind pigmentation and appetite.

Calms the inflammation switches

It inhibits NF-kB and the NLRP3 inflammasome inside cells, which lowers pro-inflammatory cytokines like TNF-alpha, IL-1beta and IL-6.

Works locally in the gut

It appears to enter intestinal cells through the PepT1 transporter, unusual for a peptide, which is why it is studied orally for gut inflammation.

The key difference

KPV vs full alpha-MSH

Same anti-inflammatory job, without the hormone's other effects.

KPV

Anti-inflammatory only

Keeps the cytokine-calming action, acts without engaging melanocortin receptors, and so avoids the pigmentation and appetite changes. Small enough to work orally.

Appeal: targeted, fewer off-target effects

Full alpha-MSH

Hormone with many jobs

The parent hormone is anti-inflammatory too, but through melanocortin receptors it also drives pigmentation and appetite, which is often not what you want.

Trade-off: broader, more hormonal effects

KPV also appears in blends like KLOW and GLOW.

Evidence

What the research shows

A real but preclinical record, concentrated on gut inflammation.

Mouse IBD models
Reducedintestinal inflammation

In murine models of inflammatory bowel disease, KPV lowered inflammation, supporting the anti-inflammatory potential of the melanocortin-derived tripeptide.

Kannengiesser et al., Inflamm Bowel Dis 2008 (PMID 18092346)

How it reaches the gut
PepT1uptake, local anti-inflammation

KPV was taken up by intestinal cells through the PepT1 transporter and reduced inflammation locally, the basis for oral, gut-targeted use.

Dalmasso et al., Gastroenterology 2008 (PMID 18061177)

The gap
No trialshuman efficacy untested

There are no completed human clinical trials specific to KPV. The gut and skin uses are extrapolated from animal and cell work, not confirmed in people.

Preclinical evidence base

The full breakdown: KPV human studies.

Dosing

How it is dosed

Two routes, depending on the target, and neither set by a human trial.

Oral, gut-focused
500mcg–1mg per day

Often an enteric-coated capsule on an empty stomach, for 4 to 8 weeks, so it survives stomach acid and reaches the intestine.

Topical, skin-focused
Topical formulation

Applied to the skin for inflammatory skin issues. Concentrations vary by preparation.

Educational information, not medical advice; dosing should come from a prescriber. Check your math with the dosage calculator.

Safety

Side effects

Reported as well tolerated in preclinical work, with no human safety trials to lean on.

  • Oral use: generally well tolerated in animal studies, with mild digestive upset the main practical concern.
  • Topical use: local irritation at the application site is possible.
  • Unknown: long-term human safety is not established, since there are no completed human trials.
  • Source quality: research-grade material is not tested for identity, purity or sterility.

Caution: inflammatory gut and skin conditions deserve a real diagnosis. KPV is not a substitute for evaluating what is actually driving the inflammation. Talk to a provider first.

A fit woman in her thirties taking an oral capsule with a glass of water in a bright, clean kitchen in the morning
Legal status

KPV's legal status in 2026

Prescription compounding

Under the October 2026 draft HHS policy, licensed 503A pharmacies can compound KPV acetate by the topical and oral routes, by prescription, single-ingredient and fully tested.

Not FDA-approved

The FDA panel voted to recommend it in July 2026, but it is not on the 503A list yet and is not approved for any medical use. The policy is a draft and nonbinding.

Research versions

KPV sold as a research chemical is for laboratory use only, not for human consumption, and is not covered by the HHS policy.

Updates: FDA peptide status tracker · how to get peptides legally.

Track it

What to monitor

Because the target is inflammation, the signal is symptoms plus a general inflammation marker.

  • hs-CRP as a general marker of inflammation, at baseline and later
  • Gut or skin symptoms, scored on the same simple scale over the course
  • Each dose and route, since oral and topical target different problems

The dashboard logs doses and symptoms, and Lab Analysis tracks markers like CRP over time.

A fit man in his thirties with clear skin preparing a fresh anti-inflammatory meal of vegetables and fish at a sunlit counter

Frequently asked questions

What is KPV?

KPV is a tripeptide made of just three amino acids, Lysine-Proline-Valine, the C-terminal tail of alpha-melanocyte-stimulating hormone (alpha-MSH). It keeps the anti-inflammatory activity of alpha-MSH while dropping that hormone's pigmentation and appetite effects, and it is studied mainly for gut and skin inflammation.

How does KPV work?

Unusually for an alpha-MSH fragment, it does not meaningfully bind melanocortin receptors at normal concentrations. Instead, preclinical research points to a receptor-independent, intracellular action: KPV inhibits NF-kB nuclear translocation and the NLRP3 inflammasome, which lowers pro-inflammatory cytokines like TNF-alpha, IL-1beta and IL-6. It also appears to enter intestinal and immune cells through the PepT1 transporter, which is why it is studied for gut inflammation specifically.

Is KPV FDA-approved or legal?

KPV is not FDA-approved for any indication. On July 24, 2026 the FDA's advisory committee voted to recommend KPV for the 503A compounding list, and the October 2026 HHS draft policy lets licensed 503A pharmacies compound KPV acetate by the topical and oral routes, by prescription, under strict testing and labeling rules. That is not FDA approval, it is a draft and nonbinding, and it does not cover research-chemical sellers, who market KPV for laboratory use only.

What is the typical KPV dose?

No human clinical trial has established a dose. Research-community protocols for gut use commonly cite roughly 500mcg to 1mg orally, often as an enteric-coated capsule taken on an empty stomach for 4 to 8 weeks, and topical formulations are used for skin. The enteric coating is meant to get it past stomach acid to the intestine. Treat these as hedged conventions, not validated clinical doses, and get any medical use from a prescriber.

What is KPV studied for?

Mostly inflammation. In animal and cell studies it reduced intestinal inflammation in colitis models, which is the basis for interest in inflammatory bowel conditions, and it is also used topically for inflammatory skin issues. The evidence is preclinical: there are no completed human clinical trials specific to KPV, so these are research directions rather than proven treatments.

Why is KPV taken orally when most peptides are not?

Most peptides are broken down in the stomach and gut before they can act. KPV is unusual in that cell and mouse studies suggest it can enter intestinal cells through the PepT1 transporter and keep working locally in the gut. That is why gut-focused protocols use oral, often enteric-coated, KPV rather than injection, though this is a preclinical finding, not a human-validated formulation.

How is KPV different from BPC-157?

They are often grouped together for gut health but work differently. BPC-157 is studied broadly for tissue repair and healing. KPV is a focused anti-inflammatory that calms cytokine signaling through NF-kB and the inflammasome. They are sometimes combined in blends, but KPV is the inflammation-calming piece rather than a general healing peptide.

Track your protocol

Log doses, symptoms and inflammation markers in one place, and see what is actually changing. Free.

Sources

  1. Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-331. PMID 18092346
  2. Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. PMID 18061177
  3. FDA Pharmacy Compounding Advisory Committee vote, July 24, 2026, and the October 2026 HHS draft 503A peptide compounding policy (KPV acetate, topical and oral). AJMC summary

This content is for informational purposes only and is not medical advice. KPV is not FDA-approved in the United States. A July 2026 FDA advisory vote in its favor is nonbinding, and the October 2026 HHS compounding policy is a draft. The evidence for KPV is preclinical, with no completed human trials. Research-grade KPV is sold for laboratory use only, not for human consumption. Always consult a qualified healthcare provider before considering any peptide protocol.